Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

相似书籍

• A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy
  由: Emi Hata, et al.
  出版: (2025-01-01)
• Valproate, risperidone, and paliperidone: A case of valproate-induced hyperammonemic encephalopathy
  由: Kyle Wesselman, PharmD candidate, MA, BS, et al.
  出版: (2024-02-01)
• The impact of the COVID-19 pandemic on the trend of prescribing long-acting injections of paliperidone and risperidone in Central Serbia
  由: Milena Stojkovic, et al.
  出版: (2023-12-01)
• The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
  由: Christopher Evernden, BSc, BScPharm, ACPR, et al.
  出版: (2021-09-01)
• Development of the Swedish anticholinergic burden scale (Swe-ABS)
  由: Tanja Rube, et al.
  出版: (2023-08-01)